News
Press Releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Aug 5, 2019Tuesday, August 13, 2019, 8:00 a.m. EDTNEW YORK, Aug. 05, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- Jul 2, 2019
NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- May 31, 2019Design of Phase 2 Open-Label Multicenter Study in Progressive MS Outlined
NEW YORK and SEATTLE, May 31, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- May 30, 2019
NEW YORK, May 30, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...
- May 28, 2019Chaim Lebovits, President & CEO Corporate Presentation, June 4, 2019 -
NEW YORK, May 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced...
- May 28, 2019
NEW YORK, NY, May 28, 2019, -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating neurodegenerative diseases,...
- May 13, 2019BrainStorm CEO to Present at the World Advanced Therapy and Regenerative Medicine Congress in London
NEW YORK and LONDON, May 13, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (Nasdaq: BCLI), a leading developer of adult stem cell technologies for neurodegenerative diseases,...
- May 10, 2019BrainStorm Announces Financial Results for the First Quarter of 2019 and Provides a Corporate UpdateHighlights Scientific Advances and Continued Progress in NurOwn® ALS Phase 3 Trial and Progressive MS Phase 2 Trial;
NEW YORK, May 10, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapies for neurodegenerative diseases, announced today...
- Apr 30, 2019
NEW YORK, April 30, 2019 (GLOBE NEWSWIRE) -- Brainstorm-Cell Therapeutics Inc., (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative disease, today announced...
- Mar 28, 2019Abstracts to highlight NurOwn® mechanism of action and correlation of Phase 2 clinical outcomes with ALS disease biomarkers
NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leader in developing innovative autologous cellular therapies for highly debilitating...